NDAORALTABLET
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
HEMADY (dexamethasone) by Bridge Therapeutics is corticosteroid hormone receptor agonists [moa]. First approved in 2019.
Drug data last refreshed 10h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEMADY (dexamethasone) is an oral corticosteroid tablet that acts as a hormone receptor agonist to suppress immune and inflammatory responses. It is a long-established generic active pharmaceutical ingredient reformulated under brand name by Bridge Therapeutics. The product targets patients requiring systemic corticosteroid therapy across multiple inflammatory and autoimmune conditions.
$0.159MPart D
Peak11.4 years to LOEProduct is in peak commercial phase with modest Medicare spending ($159K, 657 claims in 2023), indicating limited market penetration or niche positioning relative to generic dexamethasone alternatives.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
Started Jan 2027
260 enrolled
Light Chain (AL) Amyloidosis
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
Started Oct 2026
20 enrolled
Multiple Myeloma
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Started Oct 2026
26 enrolled
Philadelphia Positive Acute Lymphoblastic Leukemia
Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas
Started Oct 2026
80 enrolled
High-grade Gliomas (HGG)
Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Started Oct 2026
228 enrolled
Relapsed / Refractory Multiple Myeloma
Worked on HEMADY at Bridge Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.